Achieve Pharma Regulatory Compliance and Faster Approvals with Pharmatech Associates

They’re two different regulatory routes with different evidentiary burdens. Clearance generally applies to moderate-risk medical devices under a 510(k), where you demonstrate substantial equivalence to a legally marketed predicate. Approval applies to drugs and biologics through an NDA or BLA, and to high-risk devices through a PMA, where you must demonstrate safety and efficacy with your own data. Knowing which route your product falls under—especially for combination products—shapes your entire development plan, and getting it wrong is expensive to correct.

We do more than just assemble documents. Effective pharmaceutical regulatory affairs work starts upstream, influencing study design, lot strategy, and characterization so the evidence you generate matches what reviewers will ask for. From there, we build the roadmap, prepare and defend the submission, manage agency interactions, and handle lifecycle requirements after approval.

The earlier you start, the better your results. The regulatory strategies that shorten timelines are the ones set before pivotal decisions are locked—raw material sourcing, analytical methods, manufacturing scale. Waiting until you’re drafting a filing means you’re documenting choices rather than optimizing them. However, just because you’re further along in the process doesn’t mean Pharmatech can’t help you find a solution. We’re able to jump into the process at any stage to help you resolve potential regulatory findings. 

Your clinical trials generate the evidence your submission stands on, so the CMC package, comparability plan, and control strategy behind those trials need to anticipate review. Changing your process mid-program without a comparability protocol in place is one of the most common ways sponsors turn a clinical success into a regulatory delay.

A BLA covers biologics—monoclonal antibodies, cell and gene therapies, vaccines, and similar products—while an NDA covers small molecule drugs. The distinction matters most in CMC. A BLA carries heavier expectations around process characterization, comparability, potency assays, and manufacturing control, because with biologics the process substantially defines the product. We help you build a BLA package where the manufacturing story and the clinical story hold together.

Yes. We work with generic drug sponsors on ANDA strategy and submissions, including complex generics where bioequivalence and characterization expectations aren’t fully defined. Our technical depth matters most in those cases where there’s no clean precedent to follow.

We build one unified strategy rather than multiple disparate strategies. Health authorities apply different risk tolerances and evidentiary standards to the same data, so we develop harmonization strategies that identify where requirements converge and where they genuinely diverge. Then, we sequence your submissions accordingly. We support programs across the U.S., EU, Canada, Mexico, and Japan.

This is where technical depth matters most. We work across the innovation spectrum, from first-in-class therapies to complex generics and biosimilars, and we architect defensible pathways even where regulatory expectations are fragmented or not fully defined.

Yes. We handle preparation, facilitation, and representation—including pre-IND and end-of-Phase II meetings. We help you anticipate the questions, align your data behind a clear position, and use the meeting to reduce risk rather than create it.

Yes. Our submission-readiness assessments review your data package against agency expectations, flag gaps, and deliver an actionable remediation plan before you file—so a preventable deficiency doesn’t cost you a review cycle.

We’re built to move fast. In many cases, we can begin within days—and you can be on a call with a subject matter expert within hours of connecting with us.